AZM treatment increased RV-induced IFN-β and IFN-λ protein release and reduced viral progeny in patients with non-atopic asthma, and a similar trend was observed in atopic asthma, and regardless of eosinophilia. This evidence concerns the gene IFNB1 and atopic asthma.